Results 41 to 50 of about 53,515 (238)
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Background In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients.
Revicki Dennis A +10 more
doaj +1 more source
BackgroundThe treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM ...
Zhuo-miao Ye +4 more
doaj +1 more source
Background Immune checkpoint blockade such as ipilimumab and anti-PD1 monoclonal antibodies have significantly improved survival in advanced melanoma.
Annie Wong +11 more
doaj +1 more source
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Background Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1 ...
Bart Neyns +46 more
doaj +1 more source
Background Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases.
Mark T. J. van Bussel +2 more
doaj +1 more source
Ipilimumab cystic hypophysitis mimicking metastatic melanoma
Ipilimumab is an immunotherapeutic agent used in the treatment of metastatic melanoma, and is known to cause hypophysitis in some patients. Magnetic resonance imaging of ipilimumab-induced hypophysitis typically shows diffuse enlargement of the pituitary
John Wallace, BS +3 more
doaj +1 more source
Ipilimumab and radiation therapy for melanoma brain metastases [PDF]
Ipilimumab, an antibody that enhances T‐cell activation, may augment immunogenicity of tumor cells that are injured by radiation therapy. We hypothesized that patients with melanoma brain metastasis treated with both ipilimumab and radiotherapy would ...
Christopher D. Lao +9 more
core +1 more source
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov ...
Xiaomin Wan +9 more
doaj +1 more source
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source

